{"id":83362,"date":"2022-11-04T07:12:00","date_gmt":"2022-11-04T00:12:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022110407120083362"},"modified":"2022-11-04T22:37:42","modified_gmt":"2022-11-04T14:37:42","slug":"%e3%80%902022-ash%e3%80%91orr%e9%ab%98%e8%be%be98%ef%bc%81%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e8%81%94%e5%90%88btk%e6%8a%91%e5%88%b6%e5%89%82%e6%b2%bb%e7%96%97","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022110407120083362","title":{"rendered":"\u30102022 ASH\u3011ORR\u9ad8\u8fbe98%\uff01\u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u8054\u5408BTK\u6291\u5236\u5242\u6cbb\u7597R\/R CLL\/SLL\u7814\u7a76\u8fdb\u5c55\u5165\u9009\u53e3\u5934\u62a5\u544a"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02<\/span>2022\u5e7411\u67084\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u8981\u54c1\u79cdBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u5355\u836f\u6216\u8054\u5408\u6cbb\u7597\u521d\u6cbb\u3001\u590d\u53d1\u6216\u96be\u6cbb\uff08R\/R\uff09\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403II\u671f\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u6570\u636e\u83b7\u9009\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u3002\u6b64\u4e3aAPG-2575\u8054\u5408\u5e03\u9c81\u987f\u6c0f\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08BTKi\uff09acalabrutinib\u6216\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u9996\u6b21\u6570\u636e\u516c\u5e03\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u4e9a\u76db\u533b\u836f\u5171\u6709\u4e09\u4e2a\u65b0\u836f\uff08\u8010\u7acb\u514b®<\/sup>\u3001APG-2575\u3001APG-115\uff09\u76845\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5176\u4e2d4\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002<\/p>\n

\n<\/p><\/div>\n

APG-2575\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u7684\u6570\u636e\u4f53\u73b0\u4e86\u8be5\u54c1\u79cd\u5728R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5f3a\u52b2\u7684\u5355\u836f\u548c\u8054\u5408\u6cbb\u7597\u6f5c\u529b\u3002\u6570\u636e\u663e\u793a\uff1aAPG-2575\u8054\u5408acalabrutinib\u6cbb\u7597R\/R CLL\/SLL\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe98%\uff1bAPG-2575\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u7684ORR\u8fbe87%\u3002\u6b64\u5916\uff0c \u5355\u836f\u6cbb\u7597\u7684\u7814\u7a76\u7ed3\u679c\u548c\u524d\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u76f8\u4f3c\uff0c\u518d\u6b21\u5c55\u73b0\u4e86APG-2575\u4f18\u79c0\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff1b\u800c\u8054\u5408\u6cbb\u7597\u7684\u7814\u7a76\uff0c\u7279\u522b\u662f\u548cacalabrutinib\u7684\u8054\u5408\u6cbb\u7597\u7684\u7814\u7a76\u7ed3\u679c\uff0c\u663e\u793a\u4e86\u8d85\u9ad8\u7684\u6709\u6548\u7387\u3002\u540c\u65f6\u5728\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\uff08TLS\uff09\u7684\u53d1\u751f\u7387\u548c\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u7b49\u65b9\u9762\uff0c\u8054\u5408\u6cbb\u7597\u4e5f\u4fdd\u6301\u4e86\u4e0eAPG-2575\u5355\u836f\u6cbb\u7597\u76f8\u5f53\u7684\u51fa\u8272\u5b89\u5168\u6027\u3002<\/p>\n

\u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c64\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e2022\u5e7412\u670811\u65e5\u81f314\u65e5\u5728\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a"APG-2575\u662f\u9996\u4e2a\u5728\u4e2d\u56fd\u8fdb\u5165\u4e34\u5e8a\u9636\u6bb5\u7684\u3001\u672c\u571f\u7814\u53d1\u7684Bcl-2\u6291\u5236\u5242\uff0c\u4e5f\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\u3002\u6b64\u524d\uff0c\u4e9a\u76db\u533b\u836f\u591a\u6b21\u516c\u5e03\u4e86\u8be5\u54c1\u79cd\u5355\u836f\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u79ef\u6781\u6570\u636e\uff0c\u83b7\u4e1a\u754c\u8ba4\u53ef\u548c\u5173\u6ce8\u3002<\/p>\n

Bcl-2\u6291\u5236\u5242\u4e0eBTK\u6291\u5236\u5242\u7684\u8054\u5408\u6cbb\u7597\u524d\u666f\u4e00\u76f4\u5907\u53d7\u5173\u6ce8\u4e0e\u671f\u5f85\u3002\u800c\u4eca\u5e74\uff0cAPG-2575\u5c06\u5728ASH\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u7684\u5176\u9996\u6b21\u8054\u5408acalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u6570\u636e\u5448\u73b0\u4e86\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u7597\u6548\uff0c\u8fdb\u4e00\u6b65\u8868\u660e\u8be5\u54c1\u79cd\u5728\u8054\u5408\u6cbb\u7597\u9886\u57df\u5177\u6709\u5de8\u5927\u6f5c\u529b\u548c\u4e34\u5e8a\u4ef7\u503c\uff0c\u8fd9\u4ee4\u6211\u4eec\u65e0\u6bd4\u632f\u594b\u3002<\/p>\n

\u672a\u6765\uff0c\u6211\u4eec\u5c06\u8fdb\u4e00\u6b65\u52a0\u5febAPG-2575\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ee5\u671f\u5c3d\u65e9\u5c06\u5176\u63a8\u5411\u4e0a\u5e02\uff0c\u65e9\u65e5\u60e0\u53ca\u60a3\u8005\u3002"<\/p>\n

\n\n\n\n\n\n\n\n\n
\n

\u4ea7\u54c1<\/b><\/span><\/p>\n

 <\/p>\n<\/td>\n

\n

\u6458\u8981<\/b><\/span><\/p>\n

 <\/p>\n<\/td>\n

\n

\u7f16\u53f7<\/b><\/span><\/p>\n

 <\/p>\n<\/td>\n

\n

\u5f62\u5f0f<\/b><\/span><\/p>\n

 <\/p>\n<\/td>\n<\/tr>\n

\n

Olverembatinib<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

 <\/span><\/p>\n<\/td>\n

\n

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+<\/sup> ALL)<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/span>HQP1351<\/span>\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u8fc7\u6df1\u5ea6\u6cbb\u7597<\/span>\/<\/span>\u96be\u6cbb\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08<\/span>CML<\/span>\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08<\/span>Ph+ ALL<\/span>\uff09\u60a3\u8005\u5bf9\u4e8e<\/span>Ponatinib<\/span>\u7684\u8010\u836f<\/span><\/p>\n<\/td>\n

\n

162387<\/span><\/p>\n<\/td>\n

\n

\u53e3\u5934\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI) -Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and
CML-AP) with T315I Mutation<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/span>HQP1351<\/span>\uff09\u6cbb\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08<\/span>TKI<\/span>\uff09\u8010\u836f\u7684<\/span>T315I<\/span>\u7a81\u53d8\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u548c\u52a0\u901f\u671f\uff08<\/span>CML-CP<\/span>\u548c<\/span>CML-AP<\/span>\uff09\u60a3\u8005\u7684\u5173\u952e\u6027<\/span>II<\/span>\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6700\u65b0\u7ed3\u679c<\/span><\/p>\n<\/td>\n

\n

170698<\/span><\/p>\n<\/td>\n

\n

\u53e3\u5934\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib <\/span>(<\/span>HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China<\/span><\/p>\n

\u65b0\u578b\u7b2c\u4e09\u4ee3<\/span>BCR-ABL<\/span>\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08<\/span>TKI<\/span>\uff09\u5965\u96f7\u5df4\u66ff\u5c3c\uff08<\/span>HQP1351<\/span>\uff09<\/span>\u5728<\/span>\u4e2d\u56fd<\/span>TKI<\/span>\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08<\/span>CML<\/span>\uff09\u60a3\u8005\u4e2d\u7684<\/span>5<\/span>\u5e74\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u968f\u8bbf\u6570\u636e<\/span><\/p>\n<\/td>\n

\n

170868<\/span><\/p>\n<\/td>\n

\n

\u53e3\u5934\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

APG-2575<\/span><\/p>\n

Lisaftoclax<\/span><\/p>\n<\/td>\n

\n

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (R\/R CLL\/SLL): Initial Data from a Phase 2 Global Study<\/span><\/p>\n

APG-2575<\/span>\uff08<\/span>Lisaftoclax <\/span>\uff09\u5355\u836f\u6216\u4e0e<\/span>Acalabrutinib\/<\/span>\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u521d\u6cbb\u3001\u590d\u53d1\u6216\u96be\u6cbb\u7684\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5<\/span>\/<\/span>\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08<\/span>R\/R CLL\/SLL<\/span>\uff09\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u6297\u80bf\u7624\u6d3b\u6027\uff1a\u6765\u81ea\u4e00\u9879<\/span>II<\/span>\u671f\u5168\u7403\u6027\u7814\u7a76\u7684\u521d\u6b65\u6570\u636e<\/span><\/p>\n<\/td>\n

\n

160386<\/span><\/p>\n<\/td>\n

\n

\u53e3\u5934\u62a5\u544a<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

APG-115<\/span><\/p>\n

Alrizomadlin<\/span><\/p>\n<\/td>\n

\n

MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)<\/span><\/p>\n

MDM2-p53<\/span>\u6291\u5236\u5242<\/span>APG-115<\/span>\uff08<\/span>Alrizomadlin<\/span>\uff09\u53ef\u589e\u5f3a\u6cca\u9a6c\u5ea6\u80fa\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08<\/span>MM<\/span>\uff09\u7684\u6297\u80bf\u7624\u6d3b\u6027<\/span><\/p>\n<\/td>\n

\n

162666<\/span><\/p>\n<\/td>\n

\n

\u58c1\u62a5\u5c55\u793a<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

APG-2575\u5165\u90092022 ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u7684\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u8010\u7acb\u514b®<\/sup>\u5165\u9009ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u7814\u7a76\u7684\u6458\u8981\u8be6\u7ec6\u4fe1\u606f\u53c2\u89c1\u540c\u671f\u53d1\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u95fb\u7a3f\uff09<\/p>\n

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (R\/R CLL\/SLL): Initial Data from a Phase 2 Global Study<\/b><\/p>\n

Lisaftoclax<\/b>\uff08<\/b>APG-2575<\/b>\uff09\u5355\u836f\u6216\u4e0e<\/b>Acalabrutinib<\/b>\/<\/b>\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u5728\u521d\u6cbb\u3001\u590d\u53d1\u6216\u96be\u6cbb\u7684\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5<\/b>\/<\/b>\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08<\/b>R\/R CLL\/SLL<\/b>\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u80bf\u7624\u6d3b\u6027\uff1a\u6765\u81ea\u4e00\u9879<\/b>II<\/b>\u671f\u5168\u7403\u6027\u4e34\u5e8a\u7814\u7a76\u7684\u521d\u6b65\u6570\u636e<\/b><\/p>\n

    \n
  • \u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a<\/li>\n
  • \u6458\u8981\u7f16\u53f7\uff1a160386<\/li>\n
  • \u5206\u4f1a\u573a\uff1a642.\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\uff1a\u5728\u7814\u836f\u7269\u548c\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3<\/li>\n
  • \u62a5\u544a\u65f6\u95f4\uff1a\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f42022\u5e7412\u670812\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0b\u53485:15\/\u5317\u4eac\u65f6\u95f42022\u5e7412\u670813\u65e5\uff0c\u661f\u671f\u4e8c\uff0c\u65e9\u4e0a6:15<\/li>\n
  • \u6838\u5fc3\u8981\u70b9\uff1a<\/li>\n
      \n
    1. APG-2575\u662f\u4e00\u79cd\u7279\u5f02\u6027Bcl-2\u6291\u5236\u5242\uff0c\u5728R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u6d3b\u6027\uff0c\u5305\u62ec\u7ecfBTKi\u6cbb\u7597\u540e\u75be\u75c5\u8fdb\u5c55\uff08PD\uff09\u4e14\u4f34\u6709del\uff0817p\uff09\u7684\u60a3\u8005\u3002\u8fd9\u662fAPG-2575\u8054\u5408acalabrutinib\u6216\u5229\u59a5\u6614\u5355\u6297\u7528\u4e8eR\/R CLL\/SLL\u60a3\u8005\u7684\u6570\u636e\u9996\u6b21\u62a5\u544a\u3002\n<\/li>\n
    2. \u60a3\u8005\u6bcf\u5929\u5355\u72ec\u53e3\u670dAPG-2575\uff08400mg\uff0c600mg\u548c800mg\uff09\u6216\u4e0eacalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\u8054\u75286\u4e2a\u5468\u671f\uff0c\u6bcf28\u5929\u4e3a\u4e00\u5468\u671f\u3002\u4e3b\u8981\u76ee\u7684\u4e3a\u786e\u5b9aII\u671f\u7814\u7a76\u63a8\u8350\u5242\u91cf\uff08RP2D\uff09\u3001\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\uff0c\u5305\u62ecAPG-2575\u5355\u836f\u53ca\u8054\u5408acalabrutinib\u6216\u5229\u59a5\u6614\u5355\u6297\u7684ORR\u3002\u5728\u76d1\u6d4b\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\uff08TLS\uff09\u524d\u63d0\u4e0b\uff0c\u60a3\u8005\u91c7\u7528\u6bcf\u5929\u68af\u5ea6\u9012\u589e\u7ed9\u836f\u7684\u65b9\u5f0f\uff0c4-6\u5929\u540e\u53ef\u8fbe\u5230\u6700\u7ec8\u76ee\u6807\u5242\u91cf\uff1a\u7b2c1\u5929\uff08D1\uff0920mg\uff0cD2 50mg\uff0cD3 100mg\uff0cD4 200mg\uff0cD5 400mg\u3002\u968f\u540e\u7b2c1\u5468\u671f\u7b2c1\u5929\uff08C1D1\uff09APG-2575 \u7684\u76ee\u6807\u5242\u91cf\u4e3a400\u3001600\u6216800mg\u3002\u8054\u5408\u6cbb\u7597\u7ec4\u4e2d\u7684\u60a3\u8005\u5728\u5b8c\u6210\u68af\u5ea6\u9012\u589e\u7ed9\u836f\u8fbe\u5230\u76ee\u6807\u5242\u91cf\u540e\uff0c\u7ee7\u7eed\u63a5\u53d7\u989d\u59167\u5929\u7684APG-2575\u5148\u5bfc\u6cbb\u7597\uff0c\u7136\u540e\u5728C1D8\u65f6\u52a0\u5165acalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\uff0c\u76f4\u81f3PD\u6216\u8005\u89c2\u5bdf\u5230\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3002\n<\/li>\n
    3. \u622a\u6b622022\u5e747\u67084\u65e5\uff0c\u5171\u5165\u7ec4141\u4f8b\u60a3\u8005\u3002\u4e2d\u4f4d\u5e74\u9f8462\u5c81\uff0818-80\uff09\u300298\u4f8b\uff0870%\uff09\u4e3a\u7537\u6027\uff0c125\u4f8b\uff0889%\uff09\u60a3\u8005\u7684\u4e1c\u90e8\u80bf\u7624\u534f\u4f5c\u7ec4\uff08ECOG\uff09\u8bc4\u5206\u4e3a0-1\u5206\uff0c15\u4f8b\uff0811%\uff09\u4e3a2\u5206\u3002\u65e2\u5f80\u4e2d\u4f4d\u6cbb\u7597\u7ebf\u6570\u4e3a2\u7ebf\uff081-15\uff09\u300217\u4f8b\uff0812%\uff09\u60a3\u8005\u65e2\u5f80\u4f7f\u7528\u8fc7BTKi\uff08n=15\uff09\u548c\/\u6216venetoclax\uff08n=3\uff09\u6cbb\u7597\u51fa\u73b0PD\u3002\u8054\u5408\u7ec4\u4e2d\uff08n=95\uff09\uff0c\u5176\u4e2dTP53\u7a81\u53d8\u6216\u4f34del\uff0817p)\u670939\u4f8b\uff0841%)\uff0cdel(11q)\u670927\u4f8b\uff0828%\uff09\uff0cIGHV\u672a\u7a81\u53d8\u670936\u4f8b\uff0838%\uff09\uff0cIGHV\u7a81\u53d8\u670914\u4f8b\uff0815%)\uff0c47%\u672a\u77e5\u3002\u4e2d\u4f4d\u4f7f\u7528APG-2575 10\uff080-30\uff09\u4e2a\u5468\u671f\uff0c\u5305\u62ec\u5355\u836f\u7ec416.5\u4e2a\u5468\u671f\uff0c\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u7ec49\uff081-15\uff09\u4e2a\u5468\u671f\uff0cacalabrutinib\u8054\u5408\u7ec47\uff080-18\uff09\u4e2a\u5468\u671f\u30023\u4f8b\uff082%\uff09\u57fa\u7ebf\u5b58\u5728\u5de8\u5927\u80bf\u5757\u7684\u60a3\u8005\u62a5\u544aTLS\uff082\u4f8b\u4e34\u5e8a\uff0c1\u4f8b\u5b9e\u9a8c\u5ba4\uff09\uff0c2\u4f8b\u4e34\u5e8aTLS\u7684\u60a3\u8005\u6700\u7ec8\u5747\u5b8c\u5168\u6062\u590d\u3002\u8054\u5408\u7ec4\u4e2d\uff0cC1D8\u52a0\u5165acalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\u540e\uff0c\u672a\u89c2\u5bdf\u5230\u4efb\u4f55TLS\u53d1\u751f\u3002\n<\/li>\n
    4. \u5b89\u5168\u6027\uff1a\u5e38\u89c1\u7684\uff08>5%\uff09\u4efb\u4f55\u7ea7\u522b\u7684\u4e0d\u826f\u53cd\u5e94\uff08AE\uff09\u5305\u62ec\uff1a\u7c92\u7ec6\u80de\u51cf\u5c11\uff0830%\uff0c3\/4\u7ea7\u4e3a26%\uff09\uff0c\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\uff0826%\uff09\uff0c\u8d2b\u8840\uff0824%\uff0c3\/4\u7ea7\u4e3a12%\uff09\uff0c\u8179\u6cfb\uff0820%\uff09\uff0c\u8840\u5c0f\u677f\u51cf\u5c11\uff0817%\uff0c3\/4\u7ea7\u4e3a5%\uff09\uff0c\u9ad8\u5c3f\u9178\u8840\u75c7\u6216\u53d1\u70ed\uff08\u54049%\uff09\uff0c\u6076\u5fc3\u3001\u5934\u75db\u6216\u75b2\u52b3\uff08\u5404\u53608%\uff09\uff0c\u8c37\u8349\u8f6c\u6c28\u9176\uff08AST\uff09\u6c34\u5e73\u5347\u9ad8\uff087%\uff09\uff0c\u9ad8\u78f7\u8840\u75c7\uff086%\uff09\uff1b\u808c\u9150\u5347\u9ad8\uff086%\uff09\u3002\u9996\u6b213\u7ea7\u53ca\u4ee5\u4e0a\u7684\u8840\u7ec6\u80de\u51cf\u5c11\u53d1\u751f\u5728\u68af\u5ea6\u9012\u589e\u6216C1\u671f\u95f4\uff0c\u7f55\u89c1\u4e8eC2\uff08n=3 [2%]\uff09\u4e4b\u540e\u300213%\u60a3\u8005\u5728\u751f\u957f\u56e0\u5b50\u652f\u6301\u4e0b\u22653\u7ea7\u7684\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u7684\u4e0d\u826f\u4e8b\u4ef6\u53ef\u63a7\u3002\u672a\u89c2\u5bdf\u5230\u5242\u91cf\u9650\u5236\u6bd2\u6027\uff08DLT\uff09\u3002\u8054\u5408\u6cbb\u7597\u7ec4\u4e2d\u672a\u53d1\u73b0\u836f\u7269\u76f8\u4e92\u4f5c\u7528\u3002\n<\/li>\n
    5. \u521d\u6b65\u7597\u6548\uff1a56%\u7684\u60a3\u8005\u5728\u6bcf\u5929\u68af\u5ea6\u9012\u589e\u7ed9\u836f\u7ed3\u675f\u540e\uff0c\u6dcb\u5df4\u7ec6\u80de\u8fc5\u901f\u6062\u590d\u81f3\u6b63\u5e38\u6c34\u5e73\u3002\u5355\u836f\u7ec4\u4e2d\uff0c\u60a3\u8005\u7684ORR\u8fbe65%\uff0843\u4f8b\uff09\uff1bacalabrutinib\u8054\u5408\u7ec4\u4e2d\uff0c\u60a3\u8005\u7684ORR\u8fbe98%\uff0853\u4f8b\uff09\uff0c\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u7ec4\u4e2d\uff0c\u60a3\u8005\u7684ORR\u8fbe87%\uff0823\u4f8b\uff09\u3002\n<\/li>\n
    6. \u7ed3\u8bba\uff1a\u5728\u521d\u6cbb\u53caR\/RCLL\/SLL\u60a3\u8005\u4e2d\uff0c\u6bcf\u65e5\u68af\u5ea6\u5242\u91cf\u9012\u589e\u7ed9\u836f\u7684\u60c5\u51b5\u4e0b\uff0cAPG-2575\u5355\u836f\u6216\u4e0eacalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u7684\u5b89\u5168\u6027\u53ef\u63a7\uff0c\u5e76\u5c55\u793a\u51fa\u4e86\u4f18\u5f02\u7684\u65e9\u671f\u7597\u6548\u3002<\/li>\n<\/ol>\n<\/ul>\n

      \u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n

      \u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n

      \u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67099\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5550\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9715\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d"\u91cd\u5927\u65b0\u836f\u521b\u5236"\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879"\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730"\u53ca4\u9879"\u521b\u65b0\u836f\u7269\u7814\u53d1"\uff0c\u53e6\u5916\u627f\u62c5"\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb"\u4e13\u98791\u9879\u3002<\/p>\n

      \u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c"\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42"\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

      \u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n

      \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n

       <\/p>\n

      <\/div>\n","protected":false},"excerpt":{"rendered":"

      \u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022022\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u8981\u54c1\u79cdBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u5355\u836f\u6216\u8054\u5408\u6cbb\u7597\u521d\u6cbb\u3001\u590d\u53d1\u6216\u96be\u6cbb\uff08R\/R\uff09\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u5168\u7403II\u671f\u4e34\u5e8a\u7814\u7a76\u521d\u6b65\u6570\u636e\u83b7\u9009\u7b2c64\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u3002\u6b64\u4e3aAPG-2575\u8054\u5408\u5e03\u9c81\u987f\u6c0f\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08BTKi\uff09acalabrutinib\u6216\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u9996\u6b21\u6570\u636e\u516c\u5e03\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u4e9a\u76db\u533b\u836f\u5171\u6709\u4e09\u4e2a\u65b0\u836f\uff08\u8010\u7acb\u514b®\u3001APG-2575\u3001APG-115\uff09\u76845\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5176\u4e2d4\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002 APG-2575\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\u7684\u6570\u636e\u4f53\u73b0\u4e86\u8be5\u54c1\u79cd\u5728R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5f3a\u52b2\u7684\u5355\u836f\u548c\u8054\u5408\u6cbb\u7597\u6f5c\u529b\u3002\u6570\u636e\u663e\u793a\uff1aAPG-2575\u8054\u5408acalabrutinib\u6cbb\u7597R\/R CLL\/SLL\u7684\u5ba2\u89c2\u7f13\u89e3\u7387\uff08ORR\uff09\u8fbe98%\uff1bAPG-2575\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u7684ORR\u8fbe87%\u3002\u6b64\u5916\uff0c \u5355\u836f\u6cbb\u7597\u7684\u7814\u7a76\u7ed3\u679c\u548c\u524d\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u76f8\u4f3c\uff0c\u518d\u6b21\u5c55\u73b0\u4e86APG-2575\u4f18\u79c0\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\uff1b\u800c\u8054\u5408\u6cbb\u7597\u7684\u7814\u7a76\uff0c\u7279\u522b\u662f\u548cacalabrutinib\u7684\u8054\u5408\u6cbb\u7597\u7684\u7814\u7a76\u7ed3\u679c\uff0c\u663e\u793a\u4e86\u8d85\u9ad8\u7684\u6709\u6548\u7387\u3002\u540c\u65f6\u5728\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\uff08TLS\uff09\u7684\u53d1\u751f\u7387\u548c\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u7b49\u65b9\u9762\uff0c\u8054\u5408\u6cbb\u7597\u4e5f\u4fdd\u6301\u4e86\u4e0eAPG-2575\u5355\u836f\u6cbb\u7597\u76f8\u5f53\u7684\u51fa\u8272\u5b89\u5168\u6027\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c64\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e2022\u5e7412\u670811\u65e5\u81f314\u65e5\u5728\u7f8e\u56fd\u65b0\u5965\u5c14\u826f\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a"APG-2575\u662f\u9996\u4e2a\u5728\u4e2d\u56fd\u8fdb\u5165\u4e34\u5e8a\u9636\u6bb5\u7684\u3001\u672c\u571f\u7814\u53d1\u7684Bcl-2\u6291\u5236\u5242\uff0c\u4e5f\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\u3002\u6b64\u524d\uff0c\u4e9a\u76db\u533b\u836f\u591a\u6b21\u516c\u5e03\u4e86\u8be5\u54c1\u79cd\u5355\u836f\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u79ef\u6781\u6570\u636e\uff0c\u83b7\u4e1a\u754c\u8ba4\u53ef\u548c\u5173\u6ce8\u3002 Bcl-2\u6291\u5236\u5242\u4e0eBTK\u6291\u5236\u5242\u7684\u8054\u5408\u6cbb\u7597\u524d\u666f\u4e00\u76f4\u5907\u53d7\u5173\u6ce8\u4e0e\u671f\u5f85\u3002\u800c\u4eca\u5e74\uff0cAPG-2575\u5c06\u5728ASH\u5e74\u4f1a\u4e0a\u53e3\u5934\u62a5\u544a\u7684\u5176\u9996\u6b21\u8054\u5408acalabrutinib\/\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597R\/R CLL\/SLL\u60a3\u8005\u7684\u6570\u636e\u5448\u73b0\u4e86\u826f\u597d\u7684\u5b89\u5168\u6027\u548c\u7597\u6548\uff0c\u8fdb\u4e00\u6b65\u8868\u660e\u8be5\u54c1\u79cd\u5728\u8054\u5408\u6cbb\u7597\u9886\u57df\u5177\u6709\u5de8\u5927\u6f5c\u529b\u548c\u4e34\u5e8a\u4ef7\u503c\uff0c\u8fd9\u4ee4\u6211\u4eec\u65e0\u6bd4\u632f\u594b\u3002 \u672a\u6765\uff0c\u6211\u4eec\u5c06\u8fdb\u4e00\u6b65\u52a0\u5febAPG-2575\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ee5\u671f\u5c3d\u65e9\u5c06\u5176\u63a8\u5411\u4e0a\u5e02\uff0c\u65e9\u65e5\u60e0\u53ca\u60a3\u8005\u3002" \u4ea7\u54c1   \u6458\u8981   \u7f16\u53f7   \u5f62\u5f0f   Olverembatinib \u5965\u96f7\u5df4\u66ff\u5c3c   Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated\/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) \u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u65e2\u5f80\u63a5\u53d7\u8fc7\u6df1\u5ea6\u6cbb\u7597\/\u96be\u6cbb\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u5bf9\u4e8ePonatinib\u7684\u8010\u836f 162387 \u53e3\u5934\u62a5\u544a Updated… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-83362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=83362"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83362\/revisions"}],"predecessor-version":[{"id":83364,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/83362\/revisions\/83364"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=83362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=83362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=83362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}